MannKind Shares Down After Lung Disease Drug Trial Discontinued

Dow Jones

2025/11/10

By Adriano Marchese

MannKind shares fell in premarket trading Monday after it said it has stopped a late-stage clinical trial for a new inhaled drug aimed at treating a stubborn form of lung disease.

Shares traded 9.8% lower ahead of the morning bell at $5.08.

The company said it is discontinuing the phase 3 ICoN-1 clinical trial evaluating MNKD-101 which aimed to treat refractory nontuberculous mycobacterial lung disease, a persistent, hard-to-treat lung infection caused by environmental mycobacteria that doesn't respond well to standard antibiotic therapy.

After reviewing early results from nearly 50 patients, the biopharmaceutical company found the treatment wasn't working as expected. The lack of results prompted the concerns regarding the likelihood of achieving the study's targets, it said.

The Data Safety Monitoring Board, an independent safety board, agreed the trial should end, though they confirmed the drug was safe.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

November 10, 2025 09:20 ET (14:20 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2582687782"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582687782\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582687782?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 22:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582687782","market":"us","top_or_hot":-1,"title":"MannKind Shares Down After Lung Disease Drug Trial Discontinued","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  MannKind shares fell in premarket trading Monday after it said it has stopped a late-stage clinical trial for a new inhaled drug aimed at treating a stubborn form of lung disease. \n</p>\n<p>\n  Shares traded 9.8% lower ahead of the morning bell at $5.08. \n</p>\n<p>\n  The company said it is discontinuing the phase 3 ICoN-1 clinical trial evaluating MNKD-101 which aimed to treat refractory nontuberculous mycobacterial lung disease, a persistent, hard-to-treat lung infection caused by environmental mycobacteria that doesn't respond well to standard antibiotic therapy. \n</p>\n<p>\n  After reviewing early results from nearly 50 patients, the biopharmaceutical company found the treatment wasn't working as expected. The lack of results prompted the concerns regarding the likelihood of achieving the study's targets, it said. \n</p>\n<p>\n  The Data Safety Monitoring Board, an independent safety board, agreed the trial should end, though they confirmed the drug was safe. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 10, 2025 09:20 ET (14:20 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MannKind Shares Down After Lung Disease Drug Trial Discontinued</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMannKind Shares Down After Lung Disease Drug Trial Discontinued\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-11-10 22:20</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  MannKind shares fell in premarket trading Monday after it said it has stopped a late-stage clinical trial for a new inhaled drug aimed at treating a stubborn form of lung disease. \n</p>\n<p>\n  Shares traded 9.8% lower ahead of the morning bell at $5.08. \n</p>\n<p>\n  The company said it is discontinuing the phase 3 ICoN-1 clinical trial evaluating MNKD-101 which aimed to treat refractory nontuberculous mycobacterial lung disease, a persistent, hard-to-treat lung infection caused by environmental mycobacteria that doesn't respond well to standard antibiotic therapy. \n</p>\n<p>\n  After reviewing early results from nearly 50 patients, the biopharmaceutical company found the treatment wasn't working as expected. The lack of results prompted the concerns regarding the likelihood of achieving the study's targets, it said. \n</p>\n<p>\n  The Data Safety Monitoring Board, an independent safety board, agreed the trial should end, though they confirmed the drug was safe. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 10, 2025 09:20 ET (14:20 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2582687782","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582687782","pubTimestamp":1762784400,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"MannKind shares fell in premarket trading Monday after it said it has stopped a late-stage clinical trial for a new inhaled drug aimed at treating a stubborn form of lung disease.Shares traded 9.8% lower ahead of the morning bell at $5.08.The company said it is discontinuing the phase 3 ICoN-1 clinical trial evaluating MNKD-101 which aimed to treat refractory nontuberculous mycobacterial lung disease, a persistent, hard-to-treat lung infection caused by environmental mycobacteria that doesn't respond well to standard antibiotic therapy.After reviewing early results from nearly 50 patients, the biopharmaceutical company found the treatment wasn't working as expected. The lack of results prompted the concerns regarding the likelihood of achieving the study's targets, it said.The Data Safety Monitoring Board, an independent safety board, agreed the trial should end, though they confirmed the drug was safe.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4584":"避孕概念","MNKD":"曼恩凯德生物医疗"},"translate_title":"肺病药物试验终止后MannKind股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNKD":1.5},"content_text":"By Adriano Marchese \n\n\n \n\n\n  MannKind shares fell in premarket trading Monday after it said it has stopped a late-stage clinical trial for a new inhaled drug aimed at treating a stubborn form of lung disease. \n\n\n  Shares traded 9.8% lower ahead of the morning bell at $5.08. \n\n\n  The company said it is discontinuing the phase 3 ICoN-1 clinical trial evaluating MNKD-101 which aimed to treat refractory nontuberculous mycobacterial lung disease, a persistent, hard-to-treat lung infection caused by environmental mycobacteria that doesn't respond well to standard antibiotic therapy. \n\n\n  After reviewing early results from nearly 50 patients, the biopharmaceutical company found the treatment wasn't working as expected. The lack of results prompted the concerns regarding the likelihood of achieving the study's targets, it said. \n\n\n  The Data Safety Monitoring Board, an independent safety board, agreed the trial should end, though they confirmed the drug was safe. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 10, 2025 09:20 ET (14:20 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}